Press Release FeedGet the RSS feed
Menu

Business Wire

Summa Health Unveils Technology Transformation Stack

Business Wire

General Catalyst-backed Aidoc, Clarium, Commure, Fabric, HippocraticAl, Judi Health, Transcarent, and Verse Medical partner with Summa and HATCo to deliver more affordable, accessible, and resilient community-based healthcare, with Percepta serving as a transformation partner to build a seamless operating system

AKRON, Ohio, August 19, 2026--Summa Health and General Catalyst's Health Assurance Transformation Company (HATCo) today announced Summa's technology "stack", unveiling the first companies to partner with the system on its transformation plan. General Catalyst's HATCo acquired Summa Health in October 2025 with the vision of delivering a more proactive, accessible, and affordable system of community-based, lifelong healthcare. These companies are the first to come together to partner with the Akron-based system and work towards delivering on that vision in partnership with Summa Health and GC's HATCo.

"Turning Summa Health into a system of care that is proactive, accessible and affordable requires something this industry has never done: the companies building the next generation of healthcare infrastructure working as one, inside a community health system. I'm energized by what that will mean for patient and provider experience and outcomes in Akron and beyond," said Hemant Taneja, CEO of General Catalyst and founder and chairman of HATCo. "A system of true health assurance is made possible through the collaboration of a vibrant ecosystem of visionary tech founders and experienced health system leaders working together to reimagine healthcare."

"The first nine months were focused on achieving organizational stability and making targeted investments that support staff and ensure patients continue to receive the highest quality health care," said Daryl Tol, acting president and CEO of Summa Health and CEO of HATCo, which General Catalyst created to transform health systems into resilient, enduring organizations. "Summa is now ready to embrace technology that will enable sustainable transformation and outcomes to serve generations in the decades to come."

Summa Health employs approximately 8,000 employees across the system and SummaCare. Aidoc, Clarium, Commure, Fabric, HippocraticAl, Judi Health, Transcarent, and Verse are all backed by General Catalyst, and are working together to connect, support, and empower Summa's patients, providers and staff to improve the health of its communities and serve as a blueprint for broader healthcare transformation in the US and beyond. That includes new technology, resources and support to drive transformation enablement while addressing system fragmentation to make day-to-day operations run more smoothly, and build towards a more connected, seamless patient experience:

  1. Biotech & pharmaPfizer Inc.Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Companies: PfizerInvestigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S. NEW YORK, October 24, 2026--Pfizer I
  2. Biotech & pharmaIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--Landmark re
  3. AutomotivePerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerMore than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile WILMINGTON, Del., October 24, 2026 --
  4. ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of RecurrenceInterim analysis results from the Phase III DASL-HiCaP trial show a statistically significant 58% reduction in the risk of metastasis or death with NUBEQA® (darolutamide) versus placebo in addition to androgen deprivation therapy (ADT) and radiation therapy (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001) Four-year m
  5. FinanceSemtech CorporationSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand CAMARILLO, Calif., October 24, 2026--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices
  6. FinanceGenmab A/SGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerCompanies: IncytePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical tria